Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC)
Akerley, W. L., Rich, N. T., Egbert, L., Harker, W. G., Van Duren, T., Smit, J., Hoffman, J. M.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article